A novel combined carbohydrate antigen 19-9 and lymphocyte-to-monocyte ratio score can predict early recurrence of resectable pancreatic ductal adenocarcinoma
暂无分享,去创建一个
S. Yamaguchi | T. Maeda | K. Yugawa | Kenkichi Hashimoto | S. Nagata | K. Taketani | A. Sakai | Kozo Konishi
[1] C. Kang,et al. Systemic inflammation response index correlates with survival and predicts oncological outcome of resected pancreatic cancer following neoadjuvant chemotherapy. , 2022, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[2] T. Notake,et al. Preoperative Peripheral Blood Lymphocyte-to-Monocyte Ratio Predicts Long-Term Outcome for Patients with Pancreatic Ductal Adenocarcinoma , 2021, Annals of Surgical Oncology.
[3] K. Ishido,et al. Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma , 2021, Annals of Surgical Oncology.
[4] T. Utsunomiya,et al. Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma: A multi-institutional retrospective study. , 2021, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[5] Y. Oda,et al. Lymphocyte–C-reactive protein ratio as a prognostic marker associated with the tumor immune microenvironment in intrahepatic cholangiocarcinoma , 2021, International Journal of Clinical Oncology.
[6] L. Matrisian,et al. Estimated Projection of US Cancer Incidence and Death to 2040 , 2021, JAMA network open.
[7] M. Schell,et al. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma , 2020, BMC Cancer.
[8] Ling Lin,et al. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma. , 2020, Surgery.
[9] S. Hayami,et al. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. , 2019, Surgery.
[10] N. Yamanaka,et al. A combination of platelet-to-lymphocyte ratio and carbohydrate antigen 19-9 predict early recurrence after resection of pancreatic ductal adenocarcinoma. , 2019, Annals of translational medicine.
[11] G. Honda,et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). , 2019, Japanese journal of clinical oncology.
[12] I. Endo,et al. Role of the tumor microenvironment in pancreatic cancer , 2019, Annals of gastroenterological surgery.
[13] Jae Hoon Lee,et al. Chronologic changes in clinical and survival features of pancreatic ductal adenocarcinoma since 2000: A single‐center experience with 2,029 patients , 2018, Surgery.
[14] E. Nakakura,et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[15] San-yuan Hu,et al. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta‐analysis of prospective studies , 2017, Cancer medicine.
[16] D. Gouma,et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After , 2017, Surgery.
[17] K. Hirakawa,et al. Preoperative predictors for early recurrence of resectable pancreatic cancer , 2017, World Journal of Surgical Oncology.
[18] Zuqiang Liu,et al. Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer , 2017, Annals of Surgical Oncology.
[19] M. Rutkowska,et al. Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer , 2016, Annals of Surgical Oncology.
[20] T. Misawa,et al. The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection , 2016, World Journal of Surgery.
[21] M. Ikeguchi,et al. Prognostic indicators based on inflammatory and nutritional factors after pancreaticoduodenectomy for pancreatic cancer , 2016, Surgery Today.
[22] G. Honda,et al. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study. , 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[23] C. Sakakura,et al. Optimal duration of the early and late recurrence of pancreatic cancer after pancreatectomy based on the difference in the prognosis. , 2014, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[24] H. Furukawa,et al. Serum CA19-9 is a Significant Predictor among Preoperative Parameters for Early Recurrence after Resection of Pancreatic Adenocarcinoma , 2012, Journal of Gastrointestinal Surgery.
[25] Tae Hyun Kim,et al. CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer. , 2011, International journal of radiation oncology, biology, physics.
[26] Marcus D. Ruopp,et al. Youden Index and Optimal Cut‐Point Estimated from Observations Affected by a Lower Limit of Detection , 2008, Biometrical journal. Biometrische Zeitschrift.